AUTHOR OF THIS BLOG

DR ANTHONY MELVIN CRASTO, WORLDDRUGTRACKER

PROSTRATE CANCER

 cancer  Comments Off on PROSTRATE CANCER
Sep 302013
 

Prostate Cancer Causes

http://www.intechopen.com/books/advances-in-prostate-cancer

Advances in Prostate Cancer

Edited by Gerhard Hamilton, ISBN 978-953-51-0932-7, Hard cover, 690 pages, Publisher: InTech, Chapters published January 16, 2013 under CC BY 3.0 license
DOI: 10.5772/45948

Prostate cancer is one of the most common types of cancer in men and its treatment was constricted to surgery for confined state and androgen ablation for advanced disease until new options have become available. The present book covers a broad range of novel aspects of prostate cancer diagnosis, treatment and patient care, as well as new research on relevant cell biology. In detail, this special volume focusses on supportive modalities for prostate cancer patients, appropriate selection of novel therapeutic regimens, including inhibitors of steroidal synthesis, cytotoxic agents, as well as intermittent androgen suppression and the roles of prostate cancer stem cells and inflammatory processes.

 

http://www.intechopen.com/books/advances-in-prostate-cancer

 

http://www.intechopen.com/books/advances-in-prostate-cancer

 

http://www.intechopen.com/books/advances-in-prostate-cancer

Share

ONE LAKH PLUS VIEWS ON ALL BLOGS- DR ANTHONY CRASTO

 drugs, INDIA  Comments Off on ONE LAKH PLUS VIEWS ON ALL BLOGS- DR ANTHONY CRASTO
Sep 292013
 

 

DR ANTHONY MELVIN CRASTO Ph.D

WORLDDRUGTRACKER

ANNOUNCING ONE LAKH PLUS VIEWS ON ALL BLOGS- DR ANTHONY CRASTO

SEE ALSO

DR ANTHONY MELVIN CRASTO, Worlddrugtracker, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India, in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK- GENERICS LTD, Research centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now sSanofi, Searle India ltd, now Rpg lifesciences, etc. he is now helping millions, has million hits on google on all organic chemistry websites. His New Drug Approvals, Green Chemistry International, Eurekamoments in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 25 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He gas good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, polymorphism etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has one lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, amcrasto@gmail.com

Personal Links

 

feder-0005.gif from 123gifs.eu

amcrasto@gmail.com

email me if u like my posts

Share

The Potential of Triterpenoids in the Treatment of Melanoma

 cancer  Comments Off on The Potential of Triterpenoids in the Treatment of Melanoma
Sep 292013
 

 

READ THIS FANTASTIC CHAPTER

By J. Sarek, M. Kvasnica, M. Vlk, M. Urban, P. Dzubak and M. Hajduch
DOI: 10.5772/19582

http://www.intechopen.com/books/research-on-melanoma-a-glimpse-into-current-directions-and-future-trends/the-potential-of-triterpenoids-in-the-treatment-of-melanoma

The Potential of Triterpenoids in the Treatment of Melanoma

J. Sarek1, 2, M. Kvasnica3, M. Vlk2, 4, M. Urban5, P. Dzubak6 and M. Hajduch6

[1] Dept. of Org. Chem., IMTM, Faculty of Sciences, Palacky University, Olomouc, Czech Republic

[2] Betulinines – Chemical group, Stribrna Skalice, Czech Republic

[3] IOCB, Academy of Sciences, Prague, Czech Republic

[4] Dept. of Nuclear Chemistry, Faculty of Nuclear Sciences and Physical Engineering, CTU, Prague, Czech Republic

[5] Dept. of Chem. and Bioch., Univ. of Colorado at Boulder, Colorado, USA

[6] Lab. of Exp. Medicine, IMTM, Faculty of Medicine and Dentistry, Palacky University and University Hospital in Olomouc, Olomouc, Czech Republic

http://www.intechopen.com/books/research-on-melanoma-a-glimpse-into-current-directions-and-future-trends/the-potential-of-triterpenoids-in-the-treatment-of-melanoma

ALL THE THUMBNAILS FOR READER

Vauquelinia corymbosa (Photo: Dr. Carlos Gerardo Velazco Macías)
Figure 1. Vauquelinia corymbosa (Photo: Dr. Carlos Gerardo Velazco Macías)
Gratiola officinalis (photo: http://botanika.wendys.cz);
Figure 2. Gratiola officinalis (photo: http://botanika.wendys.cz);
Platanus acerifolia (photo: www.shutterstock.com);
Figure 3. Platanus acerifolia (photo: www.shutterstock.com);
Ziziphus Mauritiana – bark (photo: http://en.wikipedia.org)
Figure 4. Ziziphus Mauritiana – bark (photo: http://en.wikipedia.org)
Betulinic acid
Figure 5. Betulinic acid
Florida cornus – bark (photo: http://en.wikipedia.org);
Figure 6. Florida cornus – bark (photo: http://en.wikipedia.org);
Betula pendula (photo: www.shutterstock.com)
Figure 7. Betula pendula (photo: www.shutterstock.com)
Vincristine
Figure 8. Vincristine
Betulinic acid
Figure 9. Betulinic acid
Betulinic acid
Figure 10. Betulinic acid
Carboxylic acid
Figure 11. Carboxylic acid
Continue
Figure 12. Continue
Continue
Figure 13. Continue
Continue
Figure 14. Continue
Continue
Figure 15. Continue
Continue
Figure 16. Continue
Continue
Figure 17. Continue
Continue
Figure 18. Continue
Continue
Figure 19. Continue
Biotransformation of betulinic acid (1)
Figure 20. Biotransformation of betulinic acid (1)
Continue
Figure 21. Continue
Continue
Figure 22. Continue
Continue
Figure 23. Continue
Continue
Figure 24. Continue
Continue
Figure 25. Continue
Share

SIMPONI® Receives European Commission Approval for Treatment of Moderately to Severely Active Ulcerative Colitis

 drugs  Comments Off on SIMPONI® Receives European Commission Approval for Treatment of Moderately to Severely Active Ulcerative Colitis
Sep 262013
 

SIMPONI® , golimumab

http://newdrugapprovals.wordpress.com/2013/07/20/simponi-aria-golimumabfor-infusion-receives-fda-approval-for-treatment-of-moderately-to-severely-active-rheumatoid-arthritis/

First and Only Subcutaneous Biologic Treatment Administered Every Four Weeks Approved for Ulcerative Colitis

LEIDEN, The Netherlands, Sept. 23, 2013 /PRNewswire/ — Janssen Biologics B.V. (“Janssen”) announced today that the European Commission has approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.  The European Commission approval follows a positive opinion by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in July 2013 recommending the use of SIMPONI.

read all at

http://www.pharmalive.com/eu-oks-simponi-for-ulcerative-colitis

 

Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

Golimumab
Golimumab
Golimumab is a human immunoglobulin G1 mAb that is specific for human TNF2, 3, 4, 5. It was created using genetically engineered mice that were immunized with human TNF, resulting in an antibody with human-derived variable and constant regions4, 5. Golimumab binds to both the soluble and transmembrane bioactive forms of human TNF, preventing the binding of TNF to its receptors and thereby inhibiting the biological activity of TNF

In the past decade, the introduction of biologics that inhibit the activity of the pro-inflammatory cytokine tumour necrosis factor (TNF) has revolutionized the treatment of a range of immuno-inflammatory disorders, such as rheumatoid arthritis, psoriasis and Crohn’s disease1. The first two such biologics — infliximab (Remicade; Centocor/Schering-Plough), a chimeric monoclonal antibody (mAb) specific for TNF, and etanercept (Enbrel; Amgen/Wyeth), a fusion protein that contains the ligand-binding portion of the soluble TNF receptor — were approved for the treatment of rheumatoid arthritis in the late 1990s. Their use has since been expanded to other disorders, including psoriatic arthritis. In 2002, the fully human TNF-specific mAb adalimumab (Humira; Abbott) was approved for the treatment of rheumatoid arthritis and is now also approved for several other immuno-inflammatory disorders. A fourth TNF inhibitor, the PEGylated humanized TNF-specific antibody fragment certolizumab pegol (Cimzia; UCB), was approved for Crohn’s disease in 2008 and rheumatoid arthritis in May 2009.

Golimumab, in combination with MTX, is approved by the FDA for the treatment of adult patients with moderately to severely active rheumatoid arthritis. It is also approved for the treatment of adult patients with active psoriatic arthritis (alone or in combination with MTX) and for the treatment of adult patients with active ankylosing spondylitis

 

 

Share

Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan

 drugs  1 Response »
Sep 252013
 

File:Zolmitriptan.svg

ZOLMITRIPTAN

 A paper from Emcure

Four isomeric unknown impurities ranging from 0.08-0.12% were found in the purified sample of Zolmitriptan during the batch analysis by gradient reverse phase ultra performance liquid chromatography (UPLC) and their molecular weights determined by liquid chromatography mass spectroscopy (LC-MS) analysis. Subsequently, all the four impurities were isolated by flash chromatography followed by semi-preparative HPLC and characterized by 1H NMR, 13C NMR, 1H-1H COSY, HMBC, HSQC, MS spectroscopy and HPLC. The structures for these four impurities were assigned to be following
Isomeric Impurity-1: 4-((3-(2-(dimethylamino)ethyl)-4-(2-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-2: 4-((3-(2-(dimethylamino)ethyl)-2-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one-,
Isomeric Impurity-3: 4-((3-(2-(dimethylamino)ethyl)-7-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one,
Isomeric Impurity-4: 4-((3-(2-(dimethylamino)ethyl)-6-(4-((oxazolidin-4-yl)methyl)phenyl)-1H-indol-5-yl)methyl) oxazolidin-2-one
Isolation and characterization of impurities has helped us in improving the purity of API by removing these impurities using crystallization.

READ ALL THIS AT

http://www.omicsonline.org/isolation-and-structural-elucidation-of-novel-isomeric-process-related-impurities-of-zolmitriptan-2155-9872.1000165.php?aid=13012#

Neelakandan K
API Research Centre
Emcure Pharmaceutical Limited
Hinjawadi, Pune, 411057, India
Fax: +91 20 39821445
E-mail: Neelakandan.K@emcure.co.in

Volume 4, Issue 2
Research Article:  J Anal Bioanal Tech 2013, 4:165
doi: 10.4172/2155-9872.1000165
Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan
Neelakandan K, Chaudhari Ashok, Manikandan H, Santosha N, Prabhakaran B and Mukund Gurjar
Citation: Neelakandan K, Ashok C, Manikandan H, Santosha N, Prabhakaran B, et al. (2013) Isolation and Structural Elucidation of Novel Isomeric Process Related Impurities of Zolmitriptan. J Anal Bioanal Tech 4:165. doi: 10.4172/2155-9872.1000165

………….
Mukund Keshao Gurjar

Dr. Mukund Gurjar is an Executive Director and Chief Scientific Officer (Research and Development) of this Company(Emcure). He is a graduate, a post graduate and Ph.D. in Chemistry from the Nagpur University. He also holds a second Ph. D. degree in Chemistry from the London University, United Kingdom as well as a post doctoral fellowship from Toronto, Canada. Prior to joining our Company, he was the deputy director of the National Chemical Laboratory, Pune where he spent 25 years spearheading innovative and advance research in Organic Chemistry. He has over 32 years of experience in pharmaceutical sciences and is a fellow at various national and international academies. He is a member of the editorial board of the prestigious journal Organic Process Research & Development published by the American Chemical Society. For his contributions to synthetic organic chemistry involving both basic and applied research, he has been felicitated with various awards. A large number of students have obtained Ph.Ds under the supervision of Dr. Gurjar and has published more than 200 papers in various international journals. He has been associated with our Company since 2001 and also became a member of the Board in the same year.

Share

Takeda Gets Simultaneous EU OKs for Three Type 2 Diabetes Therapies

 diabetes  Comments Off on Takeda Gets Simultaneous EU OKs for Three Type 2 Diabetes Therapies
Sep 252013
 

Takeda Receives Simultaneous European Marketing Authorization for Three New Type 2 Diabetes Therapies, VipidiaTM (alogliptin) and Fixed-Dose Combinations VipdometTM (alogliptin and metformin) and IncresyncTM (alogliptin and pioglitazone)

Osaka, Japan, September 24, 2013 – Takeda Pharmaceutical Company Limited (Takeda) today announced that the European Commission has granted Marketing Authorization (MA) for VipidiaTM (alogliptin), a dipeptidyl peptidase IV (DPP-4) inhibitor, for the treatment of type 2 diabetes patients who are uncontrolled on existing therapies1-3and for the fixed-dose combination (FDC) therapies VipdometTM (alogliptin with metformin) and IncresyncTM (alogliptin with pioglitazone). The Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), issued a positive opinion for these products on July 26, 2013.http://www.pharmalive.com/takeda-gets-simultaneous-eu-oks-for-three-new-type-2-diabetes-therapies

Share

Health Canada Approves Bayer’s Hypertension Drug

 CANADA  Comments Off on Health Canada Approves Bayer’s Hypertension Drug
Sep 242013
 

 

File:Riociguat structure.svg

riociguat

Bayer Inc. announced today that the Health Canada has approved the drug Adempas (riociguat) for the treatment of inoperable, or persistent and recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgery in adult patients. Learn more…http://www.dddmag.com/news/2013/09/health-canada-approves-bayers-hypertension-drug?et_cid=3497158&et_rid=523035093&type=headline

Share

Roche Gets Breakthrough Status for Lung Cancer Drug

 breakthrough designation, Uncategorized  Comments Off on Roche Gets Breakthrough Status for Lung Cancer Drug
Sep 242013
 

 

ALECTINIB

http://www.who.int/medicines/publications/druginformation/issues/PL_108.pdf

9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-
6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile
tyrosine kinase inhibitor, antineoplastic

C30H34N4O2, CAS 1256580-46-7

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche’s alectinib – a promising investigational 2nd generation ALK inhibitor – based on data that will be presented at European Cancer Congress (ECC). Read more…http://www.dddmag.com/news/2013/09/roche-gets-breakthrough-status-lung-cancer-drug?et_cid=3497158&et_rid=523035093&type=cta

Share
 Older Entries
Follow

Get every new post on this blog delivered to your Inbox.

Join other followers: